[go: up one dir, main page]

AU2001238369A1 - Method for treating thyroid disorders - Google Patents

Method for treating thyroid disorders

Info

Publication number
AU2001238369A1
AU2001238369A1 AU2001238369A AU3836901A AU2001238369A1 AU 2001238369 A1 AU2001238369 A1 AU 2001238369A1 AU 2001238369 A AU2001238369 A AU 2001238369A AU 3836901 A AU3836901 A AU 3836901A AU 2001238369 A1 AU2001238369 A1 AU 2001238369A1
Authority
AU
Australia
Prior art keywords
thyroid disorders
treating thyroid
treating
disorders
thyroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238369A
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU2001238369A1 publication Critical patent/AU2001238369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001238369A 2000-02-15 2001-02-15 Method for treating thyroid disorders Abandoned AU2001238369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders
US09504538 2000-02-15
PCT/US2001/004990 WO2001060396A2 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Publications (1)

Publication Number Publication Date
AU2001238369A1 true AU2001238369A1 (en) 2001-08-27

Family

ID=24006701

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238369A Abandoned AU2001238369A1 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Country Status (10)

Country Link
US (6) US6524580B1 (en)
EP (1) EP1253933B1 (en)
JP (2) JP2003530320A (en)
AR (1) AR027442A1 (en)
AT (1) ATE245032T1 (en)
AU (1) AU2001238369A1 (en)
DE (1) DE60100473T2 (en)
ES (1) ES2199209T3 (en)
TW (1) TWI283177B (en)
WO (1) WO2001060396A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US8563257B2 (en) 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
AU2001270219A1 (en) * 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
EP2502930B1 (en) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982996A1 (en) 2004-09-01 2008-10-22 Allergan, Inc. Degradable clostridial toxins
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
EP1906923B1 (en) 2005-07-22 2018-01-24 The Foundry, LLC Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2662027B1 (en) 2008-05-09 2017-09-27 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
RU2446791C2 (en) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Method of ethanol sclerotherapy of cystic transformed thyroid nodules
CN104042322B (en) 2009-10-27 2017-06-06 赫莱拉公司 Delivery apparatus with coolable energy transmitting device
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
EP2842510B1 (en) 2009-11-11 2022-08-24 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
CN104321048B (en) 2012-04-13 2019-01-11 路博润高级材料公司 The compound (II) of inhibitory neuron exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP6601922B2 (en) 2015-01-09 2019-11-06 イプセン バイオイノベーション リミテッド Cationic neurotoxin
CN107921237A (en) 2015-04-27 2018-04-17 反射医学公司 Sympathetic nerve cardiopulmonary neural modulation system and method
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
JP7186228B2 (en) 2018-02-26 2022-12-08 イプセン バイオファーム リミテッド Use of ultrasound to guide injection of non-cytotoxic proteases
DE102019215585B4 (en) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság PROCEDURES FOR THE PREVENTION OF RADIATION DAMAGE IN HUMAN GLANDS
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
CN117120033A (en) 2021-03-30 2023-11-24 图拉维治疗股份有限公司 Methods and compositions for nerve ablation
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5789397A (en) * 1991-01-08 1998-08-04 Bone Care International, Inc. Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
AU5018693A (en) 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP1374886B1 (en) * 1993-06-10 2009-09-02 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2347384T3 (en) * 1993-12-28 2010-10-28 Allergan, Inc. NEUROTOXIC COMPONENT OF A BOTULINIC TOXIN TO TREAT LATE DYSCINESIA.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6063405A (en) 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP1475099B2 (en) 1997-07-15 2014-04-09 The Regents of the University of Colorado Use of botulinum toxin to treat urinary incontinence
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Also Published As

Publication number Publication date
TWI283177B (en) 2007-07-01
ES2199209T3 (en) 2004-02-16
US6716427B1 (en) 2004-04-06
ATE245032T1 (en) 2003-08-15
US6524580B1 (en) 2003-02-25
US6740321B1 (en) 2004-05-25
JP2012207030A (en) 2012-10-25
US6743424B1 (en) 2004-06-01
JP2003530320A (en) 2003-10-14
WO2001060396A2 (en) 2001-08-23
US6585970B1 (en) 2003-07-01
DE60100473D1 (en) 2003-08-21
US6447785B1 (en) 2002-09-10
WO2001060396A3 (en) 2002-03-14
AR027442A1 (en) 2003-03-26
EP1253933A2 (en) 2002-11-06
DE60100473T2 (en) 2004-04-15
EP1253933B1 (en) 2003-07-16

Similar Documents

Publication Publication Date Title
AU2001238369A1 (en) Method for treating thyroid disorders
AU2001238472A1 (en) Method for treating parathyroid disorders
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001245283A1 (en) Methods for treating aneurysms
AU2001231104A1 (en) Methods for treating diabetes
AU7085100A (en) Method for treating otic disorders
AU2002215125A1 (en) Well treatment method
AU2001247893A1 (en) Method for facilitating commercial transactions
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU7090201A (en) Method
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
AUPR152100A0 (en) Method for treating coral
AU2001277938A1 (en) Method for treating angina
HK1043935A1 (en) Method for treating copd
AU2002214487A1 (en) Method for inducing apoptiosis
GB0005867D0 (en) Method
AU2001237530A1 (en) Method
GB0118883D0 (en) Method for treating objects
GB0123898D0 (en) Method for treating objects
AU2001243297A1 (en) Method for treating or preventing depression
GB0123897D0 (en) Method for treating objects
GB0122810D0 (en) Method for treating objects
AU2001241636A1 (en) Halotherapy method
GB0020910D0 (en) Reduction method
AU2002220757A1 (en) Method for obtaining azaerythromycin